Oral semaglutide as effective as injectable

Ozempic/Wegovy sponsor trumpets results of Phase III clinical trial as its halts US ads A trial of an oral version of Novo Nordisk’s obesity and diabetes medication semaglutide, the active ingredient in high profile potential blockbuster drugs Ozempic and Wegovy, appears to deliver similar results to the incredibly popular injectable versions of the  treatments. These